Family Medicine · Riverside, CA
NPI
1881670016
Since 2005
Specialty
Family Medicine
Code 207Q00000X
Group practices
3
Medicare group memberships
Hospitals
0
Hospital affiliations
1970 University Ave
Riverside, CA, 92507
Phone (442) 286-7916
Groups this clinician bills Medicare through
Medicare paid, 2024
$9,970
163 services
Medicare patients, 2024
56
Average age 60
Drug cost, 2024
$8.6M
3,100 prescriptions
Company payments, 2025
$195
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael Robinson was code 99214 (office e&m - established), 49 times for 35 patients. In total Michael Robinson billed 163 services in 19 codes, and Medicare paid $9,970.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-06-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 49 | 35 | $86.17 | $4,222 |
| 99213 Office E&M - Established | Office | 43 | 39 | $39.24 | $1,687 |
| G0008 Administration of influenza virus vaccine | Office | 17 | 16 | $29.23 | $497 |
By year: 2022 $10K for 240 services; 2023 $10K for 232 services; 2024 $9,970 for 163 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 15 | 15 | $9.56 | $143 |
Medicare prescription drug claims, 2024
In 2024, the drug Michael Robinson prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 942 prescriptions and refills. In total Michael Robinson wrote 3,100 Medicare prescriptions that cost $8.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 942 | 942 | 110 | $3.6M |
| Tivicay Dolutegravir Sodium | 363 | 363 | 43 | $969K |
| Dovato Dolutegravir Sodium/Lamivudine | 341 | 341 | 36 | $949K |
| Prezcobix Darunavir/Cobicistat | 177 | 177 | 23 | $428K |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | 164 | 173 | 21 | $582K |
| Descovy Emtricitabine/Tenofov Alafenam | 141 | 141 | 15 | $300K |
| Juluca Dolutegravir/Rilpivirine | 135 | 135 | 14 | $464K |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | 97 | 97 | 11 | $426K |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 75 | 75 | Under 11 | $291K |
| Cabenuva Cabotegravir/Rilpivirine | 59 | 106 | 12 | $356K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 52 | 62 | 12 | $427 |
| Amlodipine Besylate Generic | 50 | 64 | Under 11 | $167 |
| Atorvastatin Calcium Generic | 30 | 48 | Under 11 | $223 |
| Valacyclovir Valacyclovir Hcl | 27 | 39 | Under 11 | $827 |
| Pifeltro Doravirine | 25 | 25 | Under 11 | $42K |
Brand drugs: 2,598 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael Robinson $195 ($195 in general payments such as food, travel and fees) from 3 companies. The largest payer was ViiV Healthcare Company with $143.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.